OXOLAMINE CITRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H19N3O.C6H8O7
Molecular Weight	437.4437
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCC1=NC(=NO1)C2=CC=CC=C2

InChI

InChIKey=RBZIGQJSMCOHSS-UHFFFAOYSA-N

InChI=1S/C14H19N3O.C6H8O7/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-9H,3-4,10-11H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula	C14H19N3O
Molecular Weight	245.3202
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C6H8O7
Molecular Weight	192.1235
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ilacprospektusu.com/ilac/619/perebron-10-mg-120-ml-surup | https://www.ncbi.nlm.nih.gov/pubmed/13720535 | https://www.ncbi.nlm.nih.gov/pubmed/7140166

Oxolamine under brand names Symphocal, Perebron is used in some countries as a cough suppressant for the treatment of pharyngitis, tracheitis, bronchitis, bronchiectasis, pertussis. Oxolamine possesses anti-inflammatory activity, which causes a reduction in the irritation of the nervous receptors of the respiratory tract.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Cough 106 Sources: https://www.ilacprospektusu.com/ilac/619/perebron-10-mg-120-ml-surup	Palliative	Approved 8429	Perebron Approved Use Unknown
Tracheitis 3 Sources: https://www.ilacprospektusu.com/ilac/619/perebron-10-mg-120-ml-surup	Palliative	Approved 8429	Perebron Approved Use Unknown
Bronchitis 51 Sources: https://www.ilacprospektusu.com/ilac/619/perebron-10-mg-120-ml-surup	Palliative	Approved 8429	Perebron Approved Use Unknown
Pertussis 3 Sources: https://www.ilacprospektusu.com/ilac/619/perebron-10-mg-120-ml-surup	Palliative	Approved 8429	Perebron Approved Use Unknown

PubMed

Title	Date	PubMed
Effect of oxolamine on cough sensitivity in COPD patients.	2002 Jan	11863211
Effect of oxolamine on anticoagulant effect of warfarin.	2006 Jan 15	16390929
Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats.	2007 Apr	17295362

Patents

Sample Use Guides

In Vivo Use Guide

In general, 15-25 mg per kilogram per day should be given by dividing four equal doses. In children over 2 years: 1-2 ml of 5 ml Adults: 2 ml of 5 ml 4 times daily 4 hours a day, after an equal amount of water.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:37:51 GMT 2023` Edited by `admin` on `Fri Dec 15 18:37:51 GMT 2023`
Record UNII	K5X4XBR694
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXOLAMINE CITRATE

Systematic Name

English

NSC-759304

Code

English

5-(2-(DIETHYLAMINO)ETHYL)-3-PHENYL-1,2,4-OXADIAZOLE CITRATE (1:1)

Systematic Name

English

OXOLAMINE CITRATE [MART.]

Common Name

English

FLOGOBRON

Brand Name

English

BREDON

Brand Name

English

BRONCATAR

Brand Name

English

PRILON

Brand Name

English

PEREBRON

Brand Name

English

SKF-9976

Code

English

Oxolamine citrate [WHO-DD]

Common Name

English

AF-438

Code

English

SKF 9976

Code

English

OXOLAMINE CITRATE [MI]

Common Name

English

Code System Code Type Description

ECHA (EC/EINECS)

217-760-6